InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: corporalagarn post# 145436

Friday, 10/18/2013 2:09:52 PM

Friday, October 18, 2013 2:09:52 PM

Post# of 345736

Does anyone have an explaination for the huge variance between predicted and actual pps?



How and why does it still amaze me that we should realize that "timelines" are off due to Fargo. Simple as that. Peregrine in the middle of a political $hitstorm re: FDA and the long history of being infested with Big Pharma allies.

Ask yourselfs this question.... what has changed since Black Monday?

1) I've heard of investigations

2) I've seen FDA internal memo for re-org which places "external Federal Authorities" in control over internal FDA authorities (which has NEVER happened before)

3) We've seen the SEC cleaning house and even dispatched to the UK

4) We've seen the MOA of PS targeting being "learned" "clarified" and "focused" and now "global"

again, I say Peregrine is sitting smack in the middle of an historic PS targeting discovery that "IS" needed for "ALL" immunotherapy to work and its one hell of a fine balancing act they are trying to work their way through trying not to disrupt Big Pharma and the FDA..... (but the results of PS targeting will absolutely change Big Pharma and the FDA's way of thinking)

Big Pharma can say all they want that they have the newest next bestest drug.... if its not targeting PS, its not the "BEST" treatment and it will prove to be "less safe" and "less effective"

At this time... its just up to Peregrine to make that message heard and known -- loud and clear, and I think they have some help doing this by someone or some groups that realize this. K&L Gates? This is like a new company going out searching for seed money.... PS targeting is the "SEED" that will grow unlike any other biotech to date.

If one Big Pharma sees this... this is when that buyout just can happen at anytime. They (Big Pharma) are not playing with their casual small biotech that they are used to rolling over and picking up for Fargo cheap money.




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News